The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study
Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations TORONTO — The More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia […]